Table 3:

Patients with non-standard BRAF alterations

ID	Age	Gender	Diagnosis	BRAF alteration (Class)	Other Alterations	TMB	Drug	Line of Therapy	Best Response	PFS Months**	OS Months**
1	41	F	colon cancer	D594G (III)	KIT D737N, APC R1399fs*9, BRIP1 I550fs*40, FLCN R477*, TP53 H179R	9	trametinib	3+	PR	11.66+	13.63+
2	83	M	lung adenocarcinoma	D594H (III), G466A (III)	EGFR exon 19 deletion, BAP1 loss, CDKN2A/B loss, RB1 splice site 2107–1_2113delGATTATGA	3	dabrafenib, trametinib	2	SD <6 months	3.15	20.83+
3	40	F	small bowel adenocarcinoma	D594N (III)	KRAS E63K, RAF1 S257L, SMAD4 R361H, W509*, SOX9 Q393fs*12, TP53 A86fs*38	4	trametinib	1	PD	1.58	3.52
4	84	F	melanoma	G469A (II)	PTEN loss exons 3–9, CDKN2A/B loss, TERT promoter-124C>T	18	dabrafenib, trametinib	3+	PR	4.34	4.34
5	66	M	non-small cell lung cancer	K601E (II)	TP53 G154V, SPTA1 E1469fs*11	N/A*	vemurafenib	2	PR	5.26	5.78
6	79	F	melanoma	N581S(III)	CDK4 amp, ERBB3 amp, MDM2 amp, TET2 splice site 4044+1G>T, T1895fs*13	8	dabrafenib, trametinib	2	PD	0.39	0.53
7	75	F	pancreatic cancer	V600_K601>E (I***)	TP53 V218E	4	Trametinib	2	SD ≥ 6 months	6.05	8.87
8	64	M	melanoma	V600R (I)	FLT1 S287F, PTEN Q214fs*5, CDKN2A loss p16INK4a and p14ARF exons 2–3, TP53 E198K, LRP1B R295*, LRP1B R3186C	N/A*	dabrafenib, trametinib	2	PR	3.15	3.15

^*N/A: tumor mutational burden was not available for these Foundation Medicine reports from 2014

^**+ indicates patient was censored prior to event occurrence

^***V600_K601>E found to constitutively activate the B-Raf kinase and the MAP kinase pathway, similar to the classical BRAF V600E mutation (35)

Abbreviations: F=female, M=male, OS=Overall Survival, PD=progressive disease, PFS=progression free survival, PR=partial response, SD=stable disease, TMB=tumor mutational burden (Mutations/Megabase), 3+=3 or more lines of therapy